Skip to content
mapperlab
← Dashboard
Stock

VCYT

VERACYTE, INC.
Health CareHealth Care ServicesLatest close $427 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
9
Current + past
New this quarter
3
Exited this quarter
1

Marquee-fund ownership over time

May 15, 2024Feb 14, 2025Feb 13, 2026May 15, 2026
Now
7

This quarter's activity

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies re-entered$29$42+42%
Citadel Advisors$31$42+33%
AQR Capital Management$31$42+33%
Point72 Asset Management re-entered$31$42+33%
D.E. Shaw re-entered$37$42+12%
Bridgewater Associates$36$42+16%
Two Sigma Investments$38$42+8%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Millennium Management→ $38+23%
Duquesne Family Office→ $37+57%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at VERACYTE, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
9
Filings · last 90d
20
Total on file
510
Recent SEC buffer
Most recent
Jun 4, 2026

30d / 90d windows measured from Jun 4, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 510 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · VERACYTE, INC.

Annual figures sourced directly from VERACYTE, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$517.15M
FY2025+16% YoY
Net income
$66.35M
FY2025+175% YoY
EPS (diluted)
$0.8200
FY2025+165% YoY
Free cash flow(?)
$126.63M
FY2025+98% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for VERACYTE, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Two Sigma InvestmentsQ2 2026open$38$42+8%
D.E. ShawQ2 2026open$38$42+8%
Renaissance TechnologiesQ2 2026open$39$42+7%
Point72 Asset ManagementQ1 2026open$36$42+15%
Bridgewater AssociatesQ1 2026open$36$46+30%
D.E. ShawQ3 2025Q1 2026$30$36+20%
Point72 Asset ManagementQ1 2025Q3 2025$41$30-27%
D.E. ShawQ4 2024Q2 2025$37$28-23%
Citadel AdvisorsQ3 2024open$31$42+33%
AQR Capital ManagementQ3 2024open$31$42+33%
Millennium ManagementQ3 2024Q2 2026$31$38+23%
Point72 Asset ManagementQ3 2024Q4 2024$31$37+19%
Renaissance TechnologiesQ3 2024Q1 2026$29$35+20%
Duquesne Family OfficeQ2 2024Q4 2024$24$37+57%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.